Clinical Trial: A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity.

U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07890870) titled 'A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity.' on Sept. 20.

Brief Summary: The goal of this clinical trial is to learn which dose of study drug IBIO-610 has the right balance of safety, tolerability and impact on body composition in participants with obesity.

Study Start Date: Dec., 2026

Study Type: INTERVENTIONAL

Condition: Obesity & Overweight

Intervention: DRUG: IBIO-610

IBIO-610; subcutaneous injection

DRUG: Placebo

Matching placebo; subcutaneous injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: iBio, Inc.

Published by HT Digital Content Services with permission from Health Daily ...